Table 2

HER2/HER4 receptor coexpression, proliferation, grade, ER status, and recurrence status

HER2Receptor coexpression
P


+

+
HER4++
Median Ki67, % (range)10.1 (0.5-38.8)13.8 (2.5-61.1)8.4 (1.6-36.0)13.4 (2-46)0.007*
Tumor grade (%)
    Low0 (0.0)2 (16.7)6 (50.0)4 (33.3)
    Intermediate6 (15.0)13 (32.5)8 (20.0)13 (32.5)NS
    High10 (12.9)27 (35.1)15 (19.5)25 (32.5)
ER status (%)
    Positive11 (73.3)21 (52.5)21 (72.4)30 (73.2)0.05
    Negative4 (26.7)19 (47.5)8 (27.5)11 (28.2)
Recurrence (%)
    No. no recurrence11 (12.2)22 (24.5)27 (30.0)30 (33.3)0.003
    No. recurred5 (12.8)20 (51.3)2 (5.1)12 (30.8)
Recurrence type
    DCIS3 (10.7)13 (46.4)2 (7.1)10 (35.8)
    Invasive2 (18.2)7 (63.6)0 (0)2 (18.2)
High grade only (%)
    No. no recurrence (%)5 (11.4)10 (22.7)13 (29.5)16 (36.4)0.015
    No. recurred (%)5 (15.2)17 (51.5)2 (6.1)9 (27.2)
Breast conserving surgery only (%)
    No. no recurrence10 (17.5)9 (15.8)20 (35.1)18 (31.6)0.001
    No. recurred4 (12.5)17 (53.1)2 (6.3)9 (28.1)
  • Abbreviation: NS, not statistically significant.

  • * Kruskal-Wallis test across all four variables.

  • χ2 test, P value between HER2-positive/HER4-negative and HER2-positive/HER4-positive DCIS.

  • χ2 test across all four groups.